A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE [apolipoprotein E] e4-stratified subjects with mild to moderate Alzheimer's disease. (REFLECT-1)
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Rosiglitazone (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms REFLECT-1
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 05 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 20 May 2009 Actual initiation date changed from Jan 2007 to Feb 2007 as reported by ClinicalTrials.gov.
- 20 May 2009 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.